Treatment for the procoagulant state in type 2 diabetes

被引：30

作者：

Colwell, JA

机构：

[1] Med Univ S Carolina, Ctr Diabet, Charleston, SC 29425 USA

[2] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2001年 / 30卷 / 04期

关键词：

D O I：

10.1016/S0889-8529(05)70225-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article discusses the procoagulent state in type 2 diabetes mellitus. There are alterations of the intrinsic coagulation system, fibrinolysis, and platelet function, which contribute to a prothrombotic state in many people with diabetes. Therapeutic approaches are presented, including a rationale for intensive glycemic regulation and aspirin therapy for diabetic individuals who are at high vascular risk.

引用

收藏

页码：1011 / +

页数：21

相关论文

共 84 条

[1] Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].

Alessi, MC ;

Peiretti, F ;

Morange, P ;

Henry, M ;

Nalbone, G ;

JuhanVague, I .

DIABETES, 1997, 46 (05) :860-867

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3]

*AM DIAB ASS, 2001, DIABETES CARE, V24, P562

[4] BIGUANIDES AND NIDDM [J].

BAILEY, CJ .

DIABETES CARE, 1992, 15 (06) :755-772

[5] Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects [J].

Calles-Escandon, J ;

Mirza, SA ;

Sobel, BE ;

Schneider, DJ .

DIABETES, 1998, 47 (02) :290-293

[6] COAGULATION AND FIBRINOLYTIC SYSTEM IMPAIRMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].

CARMASSI, F ;

MORALE, M ;

PUCCETTI, R ;

DENEGRI, F ;

MONZANI, F ;

NAVALESI, R ;

MARIANI, G .

THROMBOSIS RESEARCH, 1992, 67 (06) :643-654

[7] Fibrinogen and diabetes mellitus: Is it time for intervention trials? [J].

Ceriello, A .

DIABETOLOGIA, 1997, 40 (06) :731-734

[8] COAGULATION ACTIVATION IN DIABETES-MELLITUS - THE ROLE OF HYPERGLYCEMIA AND THERAPEUTIC PROSPECTS [J].

CERIELLO, A .

DIABETOLOGIA, 1993, 36 (11) :1119-1125

[9] EVIDENCE FOR A HYPERGLYCEMIA-DEPENDENT DECREASE OF ANTITHROMBIN-III-THROMBIN COMPLEX-FORMATION IN HUMANS [J].

CERIELLO, A ;

GIUGLIANO, D ;

QUATRARO, A ;

MARCHI, E ;

BARBANTI, M ;

LEFEBVRE, P .

DIABETOLOGIA, 1990, 33 (03) :163-167

[10] Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects -: The BIGPRO1 study [J].

Charles, MA ;

Morange, P ;

Eschwège, E ;

André, P ;

Vague, P ;

Juhan-Vague, I .

DIABETES CARE, 1998, 21 (11) :1967-1972

← 1 2 3 4 5 6 7 8 9 →